From: Cancer immunotherapy: the beginning of the end of cancer?
Biomarker | Comments | Refs |
---|---|---|
Mutational load | In general, the higher the number of mutations the better the response to immunotherapy; not the case for all tumors | |
Lymphocyte infiltrates | The presence of lymphocyte infiltrates is related to improved survival | |
PD-L1 expression | PD-L1 expression on tumor cells may potentially serve as a useful predictive biomarker for response to anti-PD1/PDL1 therapy; not the case for many tumors | |
Genetic profiling | Patients with higher baseline expression of immune-related genes generally respond better to ipilimumab | [97] |